Cargando…

P1605: OUTCOME OF SARS-COV-2 INFECTION IN HAEMATOLOGICAL CANCER PATIENTS (PTS) IN TWO DIFFERENT PANDEMIC PHASES AT A SINGLE CENTRE

Detalles Bibliográficos
Autores principales:	Rodrigues, R., Freitas, A. C., Esteves, S., Gomes da Silva, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428950/ http://dx.doi.org/10.1097/01.HS9.0000849276.63627.22

Ejemplares similares

P1605: IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA IN OLDER PATIENTS: RESULTS FROM THE SPANISH TTP REGISTRY (REPTT)
por: Seguí, Inés Gómez, et al.
Publicado: (2023)

Historia y romancero del Cid (Lisboa, 1605)
Publicado: (1973)

P1570: SARS-COV-2 HUMORAL AND CELLULAR VACCINATION RESPONSE IN PATIENTS WITH LYMPHOID HAEMATOLOGICAL MALIGNANCIES
por: Boerenkamp, L. S., et al.
Publicado: (2022)

P1609: VERY LOW MORTALITY IN DOUBLE VACCINATED IMMUNOCOMPROMISED HAEMATOLOGY PATIENTS INFECTED WITH SARS-COV-2.
por: Shaw, B., et al.
Publicado: (2022)

P1536: SARS-COV-2 INFECTIONS IN PATIENTS WITH HAEMATOLOGIC MALIGNANCIES: EFFECT OF VACCINATION AND THE DEVELOPMENT OF HYBRID IMMUNITY
por: Haggenburg, Sabine, et al.
Publicado: (2023)

P1615: AN ANALYSIS ACROSS ABO BLOOD GROUPS IN PATIENTS WITH COVID-19 INFECTION AND CORRELATION WITH HAEMATOLOGICAL BIOMARKERS, A SINGLE CENTRE STUDY
por: Shokr, H., et al.
Publicado: (2022)

1605. Differences in Clinical Characteristics of Third Generation Cephalosporin Resistance and Treatment Outcomes in Escherichia coli and Klebsiella pneumoniae Bacteremia in Patients with Liver Cirrhosis
por: Ham, Sin Young, et al.
Publicado: (2020)

Outcome of haematology patients admitted to intensive care in a tertiary centre: primary haematological diagnosis, recent chemotherapy and bone marrow transplantation are not associated with outcome
por: José, R, et al.
Publicado: (2011)

El ingenioso hidalgo Don Quijote de la Mancha 1605
por: Cervantes, Saavedra, Miguel de, 1547-1616
Publicado: (1984)

1605. Temperature Modulates the Rate of Increase of Antibiotic Resistance Across Europe
por: McGough, Sarah, et al.
Publicado: (2019)

P973: ATTRITION PROBABILITY AND PREDICTORS AMONG MULTIPLE MYELOMA PATIENTS TREATED IN AN ITALIAN HAEMATOLOGICAL TERTIARY CARE CENTRE
por: More’, Sonia, et al.
Publicado: (2023)

P1537: MORTALITY AND BURDEN OF POST-COVID-19 SYNDROME HAVE REDUCED WITH TIME ACROSS SARS-COV-2 VARIANTS IN HAEMATOLOGY PATIENTS
por: Willan, John, et al.
Publicado: (2023)

Antiviral activity of Bifidobacterium adolescentis SPM1605 against Coxsackievirus B3
por: Kim, Min Ji, et al.
Publicado: (2014)

P665: RAPID AND DEEP RESPONSES WITH ASCIMINIB IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AFTER ≥2 PRIOR TYROSINE KINASE INHIBITORS (TKIS) IN THE PHASE 3 ASCEMBL STUDY
por: Hughes, Timothy, et al.
Publicado: (2023)

P688: ASC2ESCALATE: A US PHASE 2, OPEN-LABEL, SINGLE-ARM, DOSE-ESCALATION STUDY OF ASCIMINIB MONOTHERAPY IN 2ND-LINE (2L) TREATMENT OF PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP)
por: Atallah, Ehab, et al.
Publicado: (2023)

P1521: IMPROVED CLINICAL OUTCOME OF COVID-19 IN HAEMATOLOGIC MALIGNANCY PATIENTS RECEIVING A FOURTH DOSE OF ANTI-SARS-COV-2 VACCINE: AN EPICOVIDEHA REPORT
por: Salmanton-García, Jon, et al.
Publicado: (2023)

P991: ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) POTENTIATES APOPTOSIS IN MYELOBLASTS FROM PATIENTS (PTS) WITH MYELOFIBROSIS (MF)
por: Clevenger, Tracy, et al.
Publicado: (2023)

P679: SPOTLIGHT ON THE REAL-WORLD TREATMENT OF CML PTS IN GERMANY: A RETROSPECTIVE SURVEY IN PRIVATE ONCOLOGY PRACTICES
por: Franke, Georg-Nikolaus, et al.
Publicado: (2023)

P1161: ASPEN: LONG-TERM FOLLOW-UP RESULTS OF A PHASE 3 RANDOMIZED TRIAL OF ZANUBRUTINIB (ZANU) VS IBRUTINIB (IBR) IN PATIENTS (PTS) WITH WALDENSTRÖM MACROGLOBULINEMIA (WM)
por: Dimopoulos, M., et al.
Publicado: (2022)

1605P Being a medical oncologist during the COVID-19 pandemic: Perception, expectations and concerns. OATH study
por: Tanriverdi, O.
Publicado: (2021)

Los autores, el texto , los lectores en el Quijote de 1605 /
por: Stoopen, María
Publicado: (2005)

Catálogo del archivo de la Basílica Colegiata de Guanajuato (1605-1977) /
por: Campos Rodríguez, Patricia
Publicado: (1980)

Prognosis of patients with haematological malignancies admitted to the ICU
por: Geerse, DA, et al.
Publicado: (2008)

P868: MEZIGDOMIDE (MEZI) PLUS DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM THE DOSE-EXPANSION PHASE OF THE CC-92480-MM-001 TRIAL
por: Bahlis, Nizar J, et al.
Publicado: (2023)

P785: SIX-MONTH CROVALIMAB EXTENSION IN THE PHASE 3 COMMODORE 3 STUDY: UPDATED EFFICACY AND SAFETY RESULTS IN COMPLEMENT INHIBITOR-NAIVE PATIENTS (PTS) WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
por: Liu, Hui, et al.
Publicado: (2023)

P214 Clinical course of SARS-CoV-2 infections of paediatric patients with cystic fibrosis– a single retrospective centre experience
por: Sieber, J., et al.
Publicado: (2023)

Survival of critically ill patients with haematological malignancies compared with patients without haematological malignancy
por: Pugh, R, et al.
Publicado: (2013)

P163 Effects of the SARS-CoV-2 pandemic on attendance at the cystic fibrosis centre and the definition of the microbiological status of cystic fibrosis patients in Tuscany
por: Dolce, D., et al.
Publicado: (2021)

P1718: A PROSPECTIVE MULTICENTER SURVEY ABOUT THE USE OF NEW TECHOLOGIES AND DIGITAL HEALTH TOOLS IN PATIENTS (PTS) WITH HEMATOLOGICAL MALIGNANCIES
por: Lopez-Garcia, A., et al.
Publicado: (2022)

P072 SARS-CoV-2 infection in patients with cystic fibrosis (CF) - a single centre experience
por: Vidoevska, A., et al.
Publicado: (2022)

P1106: PRELIMINARY RESULTS OF A PHASE 1 STUDY OF NOVEL BCL-2 INHIBITOR LISAFTOCLAX (APG-2575) IN CHINESE PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMAS (NHLS)
por: Sun, M., et al.
Publicado: (2022)

P1126: PHASE 1B/2A STUDY OF AZD4573 (CDK9I) AND ACALABRUTINIB IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL)
por: Strati, Paolo, et al.
Publicado: (2023)

P1162: ZANUBRUTINIB IN OLDER PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): SUBGROUP ANALYSIS OF THE MAGNOLIA STUDY
por: Opat, S., et al.
Publicado: (2022)

P1055: BROMODOMAIN AND EXTRA-TERMINAL (BET) INHIBITOR INCB057643 (LIMBER-103) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY MYELOFIBROSIS (R/R MF) AND OTHER ADVANCED MYELOID NEOPLASMS: A PHASE 1 STUDY
por: Watts, Justin M., et al.
Publicado: (2023)

P1679: HEALTH-RELATED QUALITY OF LIFE IN PATIENTS (PTS) WITH WALDENSTRÖM MACROGLOBULINEMIA (WM) TREATED WITH ZANUBRUTINIB (ZANU) VS IBRUTINIB (IBR): RESULTS FROM THE PHASE 3 ASPEN TRIAL LONG-TERM FOLLOW-UP
por: Tedeschi, Alessandra, et al.
Publicado: (2023)

P911: EVALUATION OF PROPHYLACTIC TOCILIZUMAB (TOCI) FOR THE REDUCTION OF CYTOKINE RELEASE SYNDROME (CRS) TO INFORM THE MANAGEMENT OF PATIENTS (PTS) TREATED WITH TECLISTAMAB IN MAJESTEC-1
por: van de Donk, Niels W.C.J., et al.
Publicado: (2023)

Phase II study of S‐1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma: Results of the LOGIK1605/JART‐1501 study
por: Fukuda, Minoru, et al.
Publicado: (2022)

P539: A PHASE 1 STUDY OF HMPL-306, A DUAL INHIBITOR OF MUTANT ISOCITRATE DEHYDROGENASE (IDH) 1 AND 2, IN PTS WITH RELAPSED/REFRACTORY MYELOID HEMATOLOGICAL MALIGNANCIES HARBORING IDH1 AND/OR 2 MUTATIONS
por: Hu, Lijuan, et al.
Publicado: (2023)

P-085: THE MORBIDITY AND MORTALITY OF SICKLE CELL DISEASE PATIENTS IN THE HAEMATOLOGY DEPARTMENT OF THE IGNACE DEEN HOSPITAL, CONAKRY HOSPITAL AND UNIVERSITY CENTRE
por: M., DIAKITE, et al.
Publicado: (2022)

710. Comparison of Initial CXR to CT in Patients (pts) with Hematologic Malignancy (HEM) and Documented Symptomatic Pulmonary Mucormycosis (PM)
por: Franklin, Alexander, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2cq6vefcm5sj0c346d1321q2ap